Fig. 6: Comparison of HIV-1 Env trimer immunogenicity after mRNA-LNP and recombinant protein immunization. | npj Vaccines

Fig. 6: Comparison of HIV-1 Env trimer immunogenicity after mRNA-LNP and recombinant protein immunization.

From: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

Fig. 6

a Macaque immunization regimen and biospecimen collection. b–d. Plasma IgG binding titers as log AUC to CH505 TF b gp120, c V2, and d V3. e Difference in binding titers to wildtype CH505 TF gp120 and CH505 TF gp120 with the CD4 binding site knocked out with a ∆371Ile mutation. Values above zero indicate higher binding to wildtype gp120 than the CD4 binding site mutant. f Plasma IgG binding titers as log AUC to HIV-1.MN gp41. Lines represent group mean values (n = 4 per group). g Antibody binding to HIV-1 gp160 expressed on the surface of Freestyle 293-F cells after mRNA transfection. Antibody binding is shown as mean fluorescence intensity measured by flow cytometry. Dark-colored and bright-colored bars indicate non-neutralizing and broadly neutralizing antibodies respectively. Antibody epitopes examined were: 7B2, gp41; 17B, co-receptor binding site; 19B, V3; PGT145, CH01 and PG9, V1V2-glycan; PGT125, V3-glycan; and CH65, anti-influenza heamaglutttin antibody. Independent replicates are indicated by black circles. Mean and standard error are shown for the 2–4 independent replicates.

Back to article page